

SBC Medical Group Holdings Inc. (SBCWW)

Nasdaq; healthcare; SIC 8011, Services-Offices & Clinics of Doctors of Medicine; CIK 0001930313

SBC Medical Group Holdings Inc. SBCWW; healthcare	
Grade	A ▼ A B C D E strongest fifth of 371 graded peers percentile 6.1; sampling error 2.5 points; lower is stronger
Rank	23 of 371
Profitability	C percentile 45.9
Solvency	A/B percentile 18.3
Growth and financing	A/B percentile 18.6
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$380.4M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: dilution, distress
Inputs computable	9 of 14
Graded from	filings received through Apr 30, 2026 162 days before the rescans; latest periodic filing 10-Q received Aug 13, 2026
Last close	\$0.28 2026-09-16; market equity \$0
Price used in grade	None



A, the bull
strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A from Apr 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

[illegible]

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

- Government Regulation and Environmental Matters" in this Annual Report. The Company, its subsidiaries, and the MCs also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. Environmental and social laws and regulations have tended to become increasingly stringent. There has been increased global focus on environmental and social issues and it is possible that countries may potentially adopt more stringent standards or new regulations

in these areas. To the extent regulatory changes occur in the future, they could result in, among other things, increased costs to the Company, its subsidiaries, and the MCs.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 45.9						
Gross profitability		33.5%	32.2%	42.7	372	2025-12-31
Return on invested capital		41.2%	9.3%	4.8	74	2025-12-31
Accruals ratio		8.1%	(6.6%)	90.1	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 2
Solvency, sleeve percentile 18.3						
Twelve-month failure probability		not computable	0.07%			firm-wide XBRL shares cannot be assigned to one ticker class
Altman Z double-prime		8.41	(0.31)	11.3	756	2025-12-31
Net debt to EBITDA		(1.72x)	1.82x	12.8	75	2025-12-31
Interest coverage		455.26x	(4.51x)	0.6	81	2025-12-31
Current ratio		3.78x	2.96x	48.4	839	2025-12-31
Growth and financing, sleeve percentile 18.6						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 2
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		108.5%	37.1%	28.6	104	2025-12-31
Asset growth, three years		46.9%	2.1%	8.6	704	2025-12-31
Net share issuance, one year		not computable	2.5%			firm-wide XBRL shares cannot be assigned to one ticker class


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 120,940,354 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
19	Tarsus Pharmaceuticals, Inc. (TARS)	4.9	A	fortress
				balance sheet
20	Biomarin Pharmaceutical Inc. (BMRN)	5.1	A	
21	Neurocrine Biosciences Inc. (NBIX)	5.4	A	
22	Crispr Therapeutics AG (CRSP)	5.7	A	
23	SBC Medical Group Holdings Inc. (SBC)	6.1	A	fortress
				balance sheet
24	SBC Medical Group Holdings Inc. (SBCWW) <	6.1	A	fortress
				balance sheet
25	United Therapeutics Corp. (UTHR)	6.5	A	
26	AtriCure, Inc. (ATRC)	6.8	A	
27	Intuitive Surgical Inc. (ISRG)	7.0	A	
28	iRhythm Holdings, Inc. (IRTC)	7.3	A	fortress
				balance sheet
29	Globus Medical Inc. (GMED)	7.6	A	

What the price implies

at the 2026-09-16 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	35.9%	8.0%	69
Distance from 52-week high	(6.7%)	(31.4%)	91
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.09	(0.14)	69

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$184.3M
Operating cash flow, four quarters	\$62.8M

Months of runway	not finite
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$2,086

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$127.3M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
2	assets	us-gaap:Assets	\$380.4M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
3	operating income	us-gaap:OperatingIncomeLoss	\$67.5M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$84.1M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$31.0M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
6	total debt	us-gaap:LongTermDebt	\$42.8M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
7	book equity	us-gaap:StockholdersEquity	\$248.3M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$163.8M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
9	total debt	us-gaap:LongTermDebt	\$6.6M	2024-12-31	2025-03-28	10-K	0001641172-25-001062
10	book equity	us-gaap:StockholdersEquity	\$195.1M	2024-12-31	2026-03-27	10-K	0001193125-26-127557
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$125.0M	2024-12-31	2026-03-27	10-K	0001193125-26-127557
12	net income	us-gaap:NetIncomeLoss	\$51.0M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$24.7M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
14	assets	us-gaap:Assets	\$266.1M	2024-12-31	2026-03-27	10-K	0001193125-26-127557
15	current assets	us-gaap:AssetsCurrent	\$231.2M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
16	current liabilities	us-gaap:LiabilitiesCurrent	\$61.1M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$240.4M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
18	liabilities	us-gaap:Liabilities	\$117.1M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
19	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$2.7M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
20	interest expense	us-gaap:InterestExpense	\$148,238	2025-12-31	2026-03-27	10-K	0001193125-26-127557
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$173.6M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$205.4M	2024-12-31	2026-03-27	10-K	0001193125-26-127557
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.4M	2025-12-31	2026-03-27	10-K	0001193125-26-127557
24	current assets	us-gaap:AssetsCurrent	\$184.5M	2024-12-31	2026-03-27	10-K	0001193125-26-127557
25	current liabilities	us-gaap:LiabilitiesCurrent	\$61.2M	2024-12-31	2026-03-27	10-K	0001193125-26-127557
26	assets	us-gaap:Assets	\$258.8M	2023-12-31	2025-03-28	10-K	0001641172-25-001062
27	assets	us-gaap:Assets	\$119.9M	2022-12-31	2024-03-19	10-K	0001493152-24-010402